NCT01857752终止2 期
Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 3
- 试验地点
- 1
- 主要终点
- Response rate
研究概览
简要总结
Primary Objectives:
- To investigate the response rate (complete response plus partial response) of temozolomide for 8 weeks (2 cycles), in patients with retinoblastoma metastatic to the central nervous system (mass only) in two strata:
- A. Initial diagnosis (mass)
- B. At relapse (mass)
- To determine hematologic toxicity: absolute neutrophil count (ANC), platelets and hemoglobin count.
Secondary Objectives:
- To determine the response in other metastatic sites (non target) (orbit, bone marrow, bone, lung, liver and others)
- To determine the remission rate and time to relapse on temozolomide.
- To document the response of leptomeningeal metastasis (cerebrospinal fluid) to temozolomide
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- — 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •This study must be evaluated and confirmed by the local ethics committees and institutional review board of the participating institution, in accordance to the declaration of Helsinki. Informed consent must be administered and the parent or guardian must sign the document, authorized by the Ethics Committee and human subjects (therapy can not start if the documents are not signed).
- •Patients less than 21 years of age with diagnosis of retinoblastoma with metastasis to the CNS (central nervous system) must be confirmed by an ophthalmologist and/or a pathologist; in conjunction with the pediatric oncologist.
- •Metastasis to the CNS is defined as a mass in the chiasm or other site in the CNS, confirmed by MRI and/or
- •At diagnosis
- •At relapse after conventional therapy.
- •It is acceptable to have other sites of metastatic disease: lymphatic, bone, bone marrow or others.
- •All sites of metastasis must be measured in 3 planes, in millimeters and described in POND (Pediatric Oncology Network Database*)
- •Quality of life must be 3 by Lansky and 50% by Karnofksy
- •Hemogram: Hemoglobin of 7, ANC of 750, platelets of 75K.
- •Chemistry: direct bilirubin less than 3.0, indirect bilirubin less than 4.0, AST less 5x normal and ALT 5x normal, creatinine less than 1.
- •Treatment must start not more than 15 days from diagnosis of metastatic retinoblastoma.
- •Every patient with relapse or progression into the CNS must be documented with CT scan or MRI of the brain. Other sites of relapse may be evaluated, including bone marrow.
- •Patients who are newly diagnosed should have not received any other chemotherapeutic therapy (with the exception of dexamethasone) 1 week before starting, or radiotherapy, 4 weeks before starting.
- •All patients to be included in this study must be presented to the principal investigator using Horizon Live Web-conferencing through the Cure4Kids website. Eligibility and target CNS sites will be determined, as well as non-target sites.
排除标准
- •Patients with metastatic to CNS with only CSF involvement are NOT ELIGIBLE.
- •Relapse patients should have NOT received chemotherapy for 4 weeks, and no patient should have received nitroureas (melphalan, CCNU or mustard). No patient should have received radiation therapy in the previous 42 days. These patients are NOT eligible.
- •Diagnosis of AIDS or HIV positive.
- •Patients with disease NOT in the CNS are NOT eligible
研究组 & 干预措施
temozolomide
Experimental
干预措施: Temozolomide (Drug)
结局指标
主要结局
Response rate
时间窗: 8 weeks
Response rate (complete response plus partial response) of temozolomide for 8 weeks (2 cycles), in patients with retinoblastoma metastatic to the central nervous system (mass only) in two strata: 1. Initial diagnosis (mass) 2. At relapse (mass)
Evaluate the toxicity suffered during each cycle of temozolamide will be evaluated using the CTCAE v3.0
时间窗: 8 weeks
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk MelanomaMalignant MelanomaNCT00539591St. Jude Children's Research Hospital29
已完成
2 期
Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052)Leukemia, Acute MyeloidMyelodysplastic SyndromeNCT00687323Merck Sharp & Dohme LLC47
已完成
2 期
Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma PatientsMelanomaNCT00525031M.D. Anderson Cancer Center55
终止
2 期
Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent GlioblastomaRECURRENT GLIOBLASTOMANCT02340156SynerGene Therapeutics, Inc.1
进行中（未招募）
1 期
Randomized Phase II Study: Temozolomide (TMZ) Concomitant to Radiotherapy followed by sequential TMZ in Advanced NSCLC Patients with CNS Metastasis versus Radiotherapy aloneEUCTR2004-001749-13-ATAESCA Pharma GesmbH92